Compare ERNA & CTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERNA | CTNT |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 6.4M |
| IPO Year | 2021 | 2023 |
| Metric | ERNA | CTNT |
|---|---|---|
| Price | $10.82 | $1.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 333.5K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.29 | ★ 57.74 |
| EPS | N/A | ★ N/A |
| Revenue | $582,000.00 | ★ $1,288,536.00 |
| Revenue This Year | N/A | $42.49 |
| Revenue Next Year | N/A | $22.22 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 182.69 |
| 52 Week Low | $0.13 | $0.02 |
| 52 Week High | $15.88 | $4.21 |
| Indicator | ERNA | CTNT |
|---|---|---|
| Relative Strength Index (RSI) | 62.49 | 46.95 |
| Support Level | $0.61 | $1.59 |
| Resistance Level | $15.88 | $1.83 |
| Average True Range (ATR) | 2.48 | 0.17 |
| MACD | -0.21 | -0.10 |
| Stochastic Oscillator | 46.03 | 9.38 |
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Cheetah Net Supply Chain Service Inc is a provider of logistics and warehousing services, historically in connection with the sale of parallel-import vehicles sourced in the U.S. to be sold in the PRC market, and more recently for the transportation of other goods between the U.S. and the PRC. Parallel-import vehicles in the PRC refer to automobiles purchased directly from overseas markets and imported for sale outside of the brand manufacturer's official distribution networks. The company operates as single report segment. The company operates in the USA and overseas.